Oramed Pharmaceuticals Inc (ORMP) — Smart Money Tracker (13F, Q2 2026)

ORMP ranks #4966 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ORMP is a top-conviction position for Gem Investment Advisors, LLC — at 5.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ORMP belongs to Mercer Global Advisors Inc /adv, but the position matters far more to Gem Investment Advisors, LLC, who has 5.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Wealth Enhancement Advisory Services, LLC has added to its ORMP position for two straight quarters, increasing it by $21.2K to reach $67.4K today.

ORMP is down 2.6% today, but institutions show net buying of $18.1M this quarter — a divergence between today's price move and the underlying institutional flow.

ORMP posted net income of $174.9M over the trailing twelve months, and currently trades at a P/E of 1.0.

• Profitable — net income of $174.9M over the trailing twelve months
• Revenue grew 49.3% year over year
• Net income improved year over year, from -$24.2M to $174.9M
• Operating cash flow was negative, using $9.1M in cash
• Current ratio of 6.98x — enough short-term assets to cover short-term liabilities
• Liabilities run x equity — a highly leveraged balance sheet worth noting